United Kingdom (UK)
Recombinant monoclonal antibody to VACV. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody SC212.
Alternative Name(s) of Target: VV
Immunogen: A phage display library of human single chain variable fragment (scFv) antibodies was constructed from the B cells of healthy volunteers boosted by the VACV vaccine. Human scFv was isolated by panning against VACV.
Specificity: The antibody is specific for VACV.
Application Notes: The scFv fragment was converted to human IgG1 (VC212). The binding affinity of VC212 was estimated by competition ELISA to IC50 values 22 µg/ml (146.67 nM). The humanized version of the antibody neutralized the VACV, as evidenced by the plaque reduction neutralization test result with a PRNT50 of ~0.16 mg/ml (~1.07 µM) (Shin et al., 2019; PMID: 30856707).
Antibody first published in:
Shin et al. Selection of Vaccinia Virus-Neutralizing Antibody from a Phage-Display Human-Antibody Library J Microbiol Biotechnol. 2019 Apr 28;29(4):651-657. PMID:30856707
Note on publication:
The original paper describes the generation and characterization of the antibody.